Personalis (Personalis) ROCE % : -30.32% (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Personalis ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Personalis's annualized ROCE % for the quarter that ended in Mar. 2024 was -30.32%.

Personalis ROCE % Historical Data

The historical data trend for Personalis's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Personalis ROCE % Chart

Personalis Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-52.53

-26.46

-22.84

-36.20

-49.43

Personalis Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-45.98	-41.67	-56.06	-57.14	-30.32

Personalis ROCE % Calculation

Personalis's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-108.103	/	( ( (292.7 - 33.131)	+	(225.099 - 47.234) )	/ 2 )
	=	-108.103	/	( (259.569	+	177.865)	/ 2 )
	=	-108.103	/	218.717
	=	-49.43 %

Personalis's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-51.808	/	( ( (225.099 - 47.234)	+	(195.276 - 31.373) )	/ 2 )
	=	-51.808	/	( ( 177.865	+	163.903 )	/ 2 )
	=	-51.808	/	170.884
	=	-30.32 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Personalis (NAS:PSNL) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Personalis ROCE % Related Terms

Thank you for viewing the detailed overview of Personalis's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Personalis (Personalis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Personalis Inc (NAS:PSNL) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

04X:Germany

Address

6600 Dumbarton Circle, Fremont, CA, USA, 94555

Website

https://www.personalis.com

Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Liquid Biopsy, NeXT Dx Test, and other Pharma Research Solutions.

Executives

Richard Chen	officer: Chief Scientific Officer	C/O PERSONALIS, INC., 1330 O'BRIEN DRIVE, MENLO PARK CA 94025
Stephen Michael Moore	officer: General Counsel	C/O PERSONALIS, INC., 1330 O'BRIEN DRIVE, MENLO PARK CA 94025
Aaron Tachibana	officer: Chief Financial Officer	400 NORTH MCCARTHY BLVD, MILPITAS CA 95035
Christopher M Hall	officer: President	6600 DUMBARTON CIRCLE, FREMONT CA 94555
Kenneth J Widder	director	10070 BARNES CANYON ROAD, SAN DIEGO CA 92121
Lonnie Shoff	director	C/O PERSONALIS, INC., 1330 O'BRIEN DRIVE, MENLO PARK CA 94025
John Stephen West	director, officer: President and CEO	C/O PERSONALIS, INC., 6600 DUMBARTON CIRCLE, FREMONT CA 94555
Lightspeed Venture Partners Select Iv, L.p.	other: Affiliate of 10% Owner	2200 SAND HILL ROAD, MENLO PARK CA 94025
Olivia Kyusuk Bloom	director	C/O GERON CORP, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Myers Woodrow A Jr	director	1 N ILLINOIS SREET 2101, INDIANAPOLIS IN 46204
Llp Abingworth	10 percent owner	38 JERMYN STREET, LONDON X0 SW1Y 6DN
Ken Ludlum	director
Arif Janmohamed	other: Affiliate of 10% Owner	2200 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Lightspeed Ultimate General Partner Select Iv, L.l.c.	other: Affiliate of 10% Owner	2200 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Lightspeed General Partner Select Iv, L.p.	other: Affiliate of 10% Owner	2200 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025